Atopic Dermatitis

The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.

Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.

A recent study investigated practical issues related to the use of dupilumab for atopic dermatitis.

A study in JAMA Dermatology dove into the subject of atopic eczema, investigating the patterns of activity that may continue into adulthood.

Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.

Seborrheic dermatitis will affect roughly half of all infants, making knowing how to treat and manage it key.

In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

A retrospective cohort study published in the International Journal of American Academy of Dermatology investigated the possible association between atopic dermatitis and hidradenitis suppurativa.

A study published in Pediatric Dermatology sought to investigate whether an educational handbook could improve atopic dermatitis (AD) symptoms, caregiver confidence in AD management skills, and AD-related quality-of-life.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.

Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.

Experts put forth their top pearls to help better take care of patients. Here’s what they said.

In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.

In this video interview, Fatima Khan, MD, discusses how atopic dermatitis can be detrimental to pediatric patients sleep, how the condition can change as the patient gets older, and more.

In a session at ACAAI’s Annual Scientific Meeting, David R. Weldon, MD, FACAAI, FAAAI, demonstrates punch biopsies for allergists and discusses the importance of knowing when to collaborate with dermatologists.

Patch testing can prove very useful in patients with suspected sensitization to a variety of allergens contained in personal care products and orthopedic implants.

Helen Brough, MA, MSc, PhD, MBBS, FAAAAI, FRCPCH, discusses the role of AD skin in infants and emollient application for preventing food allergy.

In this video interview, Mark Serota, MD, highlights the key talking points from his session at the 2021 ACAAI annual scientific meeting.

Involving patients with atopic dermatitis in decisions about developing their treatment plan can lead to improved treatment outcomes and higher satisfaction, the American College of Allergy, Asthma & Immunology (ACAAI) medical director said in a luncheon presentation at the college’s 2021 Annual Scientific Symposium.

In this video interview, Jeff Yu, MD, highlights key talking points from his session on regional dermatitis and rash from the American College of Allergy, Asthma & Immunology annual scientific meeting.